Biologic Therapies for Severe Asthma

Guy G Brusselle; Gerard H Koppelman

doi:10.1056/NEJMra2032506

Biologic Therapies for Severe Asthma

Guy G Brusselle^*
, Gerard H Koppelman

^*Corresponding author for this work

Groningen Research Institute for Asthma and COPD (GRIAC)

Research output: Contribution to journal › Review article › peer-review

665 Citations (Scopus)

1310 Downloads (Pure)

Abstract

Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.

Original language	English
Pages (from-to)	157-171
Number of pages	15
Journal	New England Journal of Medicine
Volume	386
Issue number	2
DOIs	https://doi.org/10.1056/NEJMra2032506
Publication status	Published - 13-Jan-2022

Access to Document

10.1056/NEJMra2032506

Biologic Therapies for Severe AsthmaFinal publisher's version, 1.69 MBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{0b22f617ece3494ba751b9131ea3bd0f,

title = "Biologic Therapies for Severe Asthma",

abstract = "Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.",

author = "Brusselle, \{Guy G\} and Koppelman, \{Gerard H\}",

year = "2022",

month = jan,

day = "13",

doi = "10.1056/NEJMra2032506",

language = "English",

volume = "386",

pages = "157--171",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "MASSACHUSETTS MEDICAL SOC",

number = "2",

}

TY - JOUR

T1 - Biologic Therapies for Severe Asthma

AU - Brusselle, Guy G

AU - Koppelman, Gerard H

PY - 2022/1/13

Y1 - 2022/1/13

N2 - Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.

AB - Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.

U2 - 10.1056/NEJMra2032506

DO - 10.1056/NEJMra2032506

M3 - Review article

C2 - 35020986

SN - 0028-4793

VL - 386

SP - 157

EP - 171

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 2

ER -

Biologic Therapies for Severe Asthma

Abstract

Access to Document

Handle.net

Fingerprint

Cite this